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Country City Organization
Albania Tirana Aksion Plus
Austria Vienna Suchthilfe Wien gGmbH
Belgium Antwerp vzw Free Clinic
Croatia Rijeka NGO for helping people with drug use disorders “Vida”




Denmark Copenhagen Health Team for the Homeless 
Estonia Tallinn NGO Convictus Estonia
Finland Helsinki EHYT Ry/ 
A-Clinic Foundation
France Paris Fédération Addiction
Georgia Tbilisi Georgian Harm Reduction Network
Germany Berlin Deutsche Aidshilfe
Greece Athens-Salonika Positive Voice
Hungary Budapest Rights Reporter Foundation
Ireland Dublin Ana Liffey Drug Project
Italy Milan/ 
Rome
Fondazione LILA Milano Italian League for Fighting AIDS/ 
Forum Droghe
Lithuania Vilnius Coalition “I Can Live”
C-EHRN Focal Points
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Country City Organization
Luxembourg Luxembourg Jugend - an Drogenhëllef
Netherlands Amsterdam Mainline Foundation
Norway Kristiansand proLAR Nett
Poland Krakow MONAR – Krakow
Portugal Vila Nova de 
Gaia
Agência Piaget Para o Desenvolvimento
North   
Macedonia
Skopje HOPS - Healthy Option Project Skopje
Romania Bucharest CARUSEL
Russia St. Petersburg/ 
Amsterdam
Charitable Fund “Humanitarian Action”/ 
AFEW
Scotland Glasgow Scottish Drugs Forum
Serbia Novi Sad Prevent
Slovakia Bratislava Odyseus
Slovenia Ljubljana Association Stigma
Spain Barcelona Red Cross Catalonia
Sweden Stockholm Stockholm Drug Users Union
Switzerland Bern Infodrog
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Acronyms and  
abbreviations
 
 C-EHRN  Correlation – European Harm Reduction Network
 COVID-19 Coronavirus Disease
 CSO  Civil Society Organisation
 DAA  Direct-Acting Antiviral
 DCR  Drug Consumption Room
 FPs  Focal Points
 HCV  Hepatitis C Virus
 HIV	 	 Human	Immunodeficiency	Virus
 MSM  Men having Sex with Men
 NPS  New Psychoactive Substances
 NSP   Needle and Syringe Exchange Programme
 OD  Drug overdose 
 OST  Opioid Substitution Therapy
 PWID  People Who Inject Drugs
 PWUD  People Who Use Drugs
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A civil society-led monitoring of harm reduc-
tion can play an essential role in improving 
service delivery and contribute to the gener-
ation of crucial data for advocacy purpos-
es. Civil society organisations (CSO’s) work 
directly for, and with, people who use drugs 
(PWUD) and have a good understanding of 
their daily needs. Their inside knowledge is 
critical in developing adequate drug policies 
and practices.
To complement the work of other monitoring 
agencies, and to bring insight into how the 
implementation of harm reduction occurs, 
Correlation -European Harm Reduction Net-
work (C-EHRN) has published a report on Civil 
Society Monitoring of Harm Reduction in Eu-
rope since 2019. It gathers data on the expe-
riences of harm reduction service providers 
and service users at ground level, building 
on a network of national Focal Points (FPs) in 
Europe.  For the 2020 monitoring, C-EHRN in-
cludes 35 FPs in 34 countries, as shown in the 
map below. To get insight at the implementa-
tion	level,	and	to	profit	from	the	experiences	
and expertise of FPs, the 2020 monitoring fo-
cuses mostly on cities rather than countries. 
Map:  Location of C-EHRN Focal Points
Introduction
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Contextualising Harm  
Reduction in Europe
Europe represents one of the regions of the 
world with the greatest number of harm reduc-
tion services. Almost half of the countries world-
wide where Needle and Syringe Exchange 
Programmes (NSP) and Opioid Substitution 
Treatment (OST) are available, are in Europe. 
Besides,	ten	out	of	twelve	countries	with	officially	
sanctioned drug consumption rooms (DCRs) are 
European. There is no other region in the world 
where more than ninety percent of the countries 
have at least one NSP or OST site, and more than 
ninety percent of the countries reference harm 
reduction in their national drug policies. Never-
theless, geographic gaps, and an uneven dis-
tribution of services, continue to exist in Europe. 
Rural communities are particularly underserved 
in many countries, and some sub-groups of peo-
ple who use drugs experience barriers to service 
access, including women who use drugs, men 
who have sex with men (MSM), people who use 
stimulants or non-injecting methods of drug use, 
and people experiencing homelessness. Mi-
grants face similar problems in access to harm 
reduction services in Western Europe. Further-
more, stigma and discrimination against people 
who use drugs continues to exist and hinders ser-
vice access in all contexts and in all regions in 
the world, including Europe. 
“ There is no other region in the world where more than ninety percent of the countries have at least one NSP or OST site, 
and more than ninety percent 
of the countries reference 
harm reduction in their national 
drug policies.
“ Stigma and discrimination against people who use drugs continues to exist.
CCorrelationEuropeanHarm ReductionNetworkEXECUTIVE SUMMARY 
11
A continuous challenge is to identify and monitor 
if, and how, a meaningful involvement of harm 
reduction CSOs in policymaking is assured. To 
contribute to that, C-EHRN monitoring addresses 
the involvement of CSOs in drug policymaking 
in the cities and countries of the respective FPs. 
Most C-EHRN FPs are directly involved in cooper-
ation exchange with their governments, either at 
the national (80% of FPs) or the local (75% of  FPs) 
Level. The main forms of involvement are either 
to provide information, or to participate in dis-
cussion forums. To a lesser extent, FPs take part 
in the direct drafting of policies and guidelines. 
Most are also part of networks and contribute to 
data reporting in their country. 
Nevertheless, while structural cooperation be-
tween CSOs and governments exist in the ma-
jority of countries, FPs consider that most of it 
relates to lower levels of cooperation. Over 60% 
of FPs view civil society involvement as a one-
way	 information	 flow	 from	 the	 government	 to	
CSOs, rather than an interactive, constructive 
exchange of ideas and views between the two 
parties. Exchange between government and 
CSOs aims mostly at informing CSOs of new poli-
cy developments and in collecting their input on 
new developments, trends and problems. In only 
about 35-40% of the cases, FPs indicated that ex-
changes aim at discussing policies, developing 
new strategies and approaches, or improving 
services. Even when higher levels of cooperation 
occur, several CSOs feel that their inputs are not 
taken into practice. 
More than half of the FPs view government rep-
resentatives as being easily approachable by 
CSOs and that civil society can speak openly 
and frankly, and criticise the government with-
out facing repercussions or budget cuts. Nev-
ertheless, important challenges to civil society 
involvement are still present. The majority (80%) 
mentioned challenges related to a perceived 
lack of transparency from the government and 
a lack of adequate funding to CSOs, besides a 
lack of balance regarding the inclusion of per-
spectives from different stakeholders  (such as 
service providers and communities).
There remains a long path to travel for civil soci-
ety to be meaningfully involved in drug policies. 
More efforts are needed to highlight the impor-
tance of civil society participation and to guar-
antee its practical implementation.
Participation of  
Civil Society Organisations 
in policymaking
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There	 is	an	 insufficient	coverage	of	 harm	 reduc-
tion services available in Europe, especially to 
some sub-groups of PWUD. In many cities, the ex-
isting services are largely focused on, and limited 
to, people who inject opioids and services target-
ing them (especially NSP and OST), leaving behind 
those who do not inject and who use other drugs. 
Also, women who use drugs, migrants, and incar-
cerated PWUD lack access to harm reduction in a 
number of cities/countries of Europe. In addition, 
in most European cities, harm reduction services 
lack funding and political support, and need to 
be better integrated with other parts of the health 
and social care system.
Essential harm reduction 
services  
“ In most European cities, harm reduction services lack fund-ing and political support, and need to be better integrated 
with other parts of the health 
and social care system.
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People who inject drugs (PWID) account for the 
majority of new cases of hepatitis C virus (HCV) in-
fections in Europe. Nevertheless, HCV testing and 
treatment	for	PWID	remains	insufficient	in	practice.	
HCV guidelines related to PWID seem to be well 
developed. Almost all FPs reported that their 
countries have either their own national guide-
lines that include PWID. In some countries, how-
ever, a negative impact of the guidelines is not-
ed. This includes HCV treatment being prescribed 
only by specialists (9 FPs), or not being possible 
outside of the specialised healthcare system (7 
FPs), and HCV testing not being possible outside 
of the healthcare system (3 FPs).
New drugs for HCV treatment (DAA’s) are avail-
able in all countries, but there are still a range 
of perceived restrictions to their access. In 19% 
(13) of the cities, different restrictions in access to 
DDA’s were reported. Restrictions may be applied 
to people who are currently using drugs, or DAA’s 
might be available only for those engaged in an 
OST programme. The majority of C-EHRN focal 
points reported that DAA’s are used in their cities 
according	 to	 the	 official	 policy, but there were 
also four cities where there is a discrepancy be-
tween policy and practice. Discrepancies includ-
ed lack of reimbursement, and lack of access by 
PWID	despite	official	policy.		
A well-functioning continuum of care, includ-
ing low threshold and harm reduction services, 
is important for accessibility and impact of HCV 
testing and treatment. It is crucial that the same 
facilities are able to offer both HCV testing and 
treatment. Nevertheless, in Europe, this integration 
of testing and treatment at the same location is 
rare. There are still big differences within Europe as 
to where, and how, PWID can undertake a HCV 
test. Most FPs (85%) reported that in their countries, 
PWID can have a rapid test for HCV in low thresh-
old settings at harm reduction services. Rapid tests 
are also quite commonly available in drug treat-
ment (65%) and at infectious disease clinics (62%). 
PWID can get tested by a general practitioner in 
about half of the countries (44%). However, rap-
id testing for PWID at pharmacies has remained 
very rare. Confirmatory	blood	testing	for	HCV	RNA	
is most commonly available for PWID at infectious 
disease clinics (97%) and gastroenterology clinics 
(65%) but, compared to last year, their availability 
seems to have improved at drug treatment clin-
ics (50%; 35% in 2019) and at harm reduction cen-
tres (41%; 26% in 2019). PWID are most commonly 
treated for hepatitis C at infectious disease clinics 
(90%) and gastroenterology clinics (65%). In 32% 
of countries, treatment was provided at harm re-
duction services or community centres. 
Positive developments were reported in terms of 
some programmes investing more attention in 
HCV awareness campaigns, and in testing and 
treatment at their own location, in relation to 2019. 
Hepatitis C
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Drug overdose (OD) is a major cause of death 
in Europe, especially among young people. De-
spite the need, overdose prevention measures 
are not always implemented on-the-ground; at 
least, not to the extent that they are needed. 
Twenty-five	of	the	35	FPs	who	responded	to	the	
survey reported that  OD prevention is men-
tioned in at least one official policy document 
in their countries. Most of the time, guidelines 
are	set	at	the	national	level,	but	specific	interest	
groups and associations also have guidelines for 
OD prevention. Yet, in at least seven countries, 
OD	prevention	is	not	yet	featured	in	any	official	
policy documents. Even when available, FPs 
pointed out that policies and guidelines should 
be updated with recent evidence and include: 
guidelines for low-threshold access to Naloxone; 
the obligation to provide people suffering from 
an OD stigma- and punishment-free emergency 
services; and OD prevention for non-opioids and 
also address poly-drug use. 
Altogether, heroin, fentanyl and other synthetic 
opioids make up almost half of the overdoses 
FPs have frequently heard about in their cities 
during 2020. Most of these opiate-related over-
doses were linked to heroin, with a very small 
proportion related to fentanyl. Stimulants such 
as cocaine, crack cocaine and methamphet-
amine were mentioned as being involved in fre-
quent overdoses by 20% of FPs. Several overdos-
es involved the use of multiple substances. The 
typical characteristics of OD victims were: being 
in a situation of homelessness; using drugs alone 
(in a private setting or on the street); engaging in 
poly-drug use; being recently released from pris-
on, drug treatment, or other health treatment 
involving drug abstinence; lacking proper nutri-
tion and sleep; not calling for help/emergency 
services for fear of the police; and not having 
access to Naloxone. 
Naloxone is available in 80% of FP’s cities. Yet, in 
at least 6 cases, the life-saving drug was report-
ed as not available. For those FPs reporting the 
availability of Naloxone, the drug is mostly avail-
able to medical staff at hospitals, ambulanc-
es, or medical staff in harm reduction services. 
In about 60-70% of cases, it is also available 
to harm reduction staff and directly to PWUD. 
Only in 40% of cases is it available to family and 
friends of PWUD. When available in FP cities, Nal-
oxone is mostly found in its injectable form (61%), 
although intranasal is also available in 50% of the 
cases. Training is available, both for peer admin-
istration (61% of cases) and staff administration 
(57%). Slightly more than half of respondents 
mentioned that Naloxone is available for take 
home (54%) and/or distributed by drug service 
providers (54%). Nevertheless, only in a few of 
the FP cities is naloxone reimbursed by health in-
surance (21%), or available in pharmacies with-
out prescription (18%).
Overdose prevention
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In more than 60% of FP cities, OD response training 
is available, targeting medical staff, harm reduc-
tion staff and people who use opioids. In less than 
a third of cities, OD prevention training also reach-
es friends and family of PWUD and, in only about 
20%, people who use drugs other than opioids. Al-
most half of the FPs assessed that OD prevention in 
their cities is comparable to the national situation 
in their respective country. Also, almost half of the 
FPs think that their city offers better OD preven-
tion when compared to the national context. This 
shows that the OD prevention context described 
by C-EHRN Monitoring is in good part based on the 
best examples available in a country. 
Yet crucial challenges exist regarding OD pre-
vention in Europe. There is a need for setting, or 
scaling-up, DCRs and residential DCRs, as well as 
Take-Home Naloxone programmes. Access to low 
threshold access to Naloxone for PWUD and peo-
ple likely to witness an overdose is crucial, besides 
lowering the threshold of OST programme initiation 
and continuation. OD prevention for stimulants 
and poly-drug use needs to be further developed. 
Finally, stigmatisation and criminalisation of PWUD 
remains a challenge hindering OD prevention. This 
shows that, despite the general support for harm 
reduction in the European region, much needs to 
be improved in terms of supporting and securing 
the human rights of PWUD. 
“ There is a need for setting, or scaling-up, DCRs and residen-tial DCRs, as well as Take-Home Naloxone programmes.
“Despite the general support for harm reduction in the Europe-an region, much needs to be improved in terms of supporting 
and securing the human rights 
of PWUD.
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New drug trends can arise in many ways: a new 
or unknown substance that arrives on the mar-
ket; an already known drug but used by a new 
group of people; a new route of administration 
of a substance; or the combined use of different 
substances.  
A small group of FPs (8) have seen the emergence 
of a new substance entering the local market in 
their cities. These drugs include synthetic canna-
binoids, ketamine, Isotonitazene, 2C-B, crack co-
caine, and oxycodone. Most of these new drugs 
are reportedly being used by people in situation 
to homelessness, or who are suffering from mental 
health problems. 
Two-thirds of respondents mentioned no new 
developments regarding the use of known sub-
stances for the first time by any of their target 
groups. For the one-third reporting new trends, 
examples	included	young	people	sniffing	MDMA	
instead of oral intake; OST injecting (methadone 
(heptanon), buprenorphine); Oxycodone bought 
online and injected or snorted; ‘bio-drugs’ taken 
orally; crack cocaine by means of smoking; opi-
oids by injection; and chemsex drugs among 
MSM. Known PWUD using new or different routes 
of administration may also be a sign of changes 
in	the	quality	of	drugs	they	use,	or	may	reflect	a	
shift from recreational use to more problematic 
use.
Only 5 FPs mentioned having witnessed their tar-
get group(s) engaged with new combinations of 
substances in the last year. Two FPs mentioned 
the combined use of ketamine and cocaine. 
Other combinations mentioned include: canna-
bis and amphetamines; methadone and am-
phetamines; and combinations of various fake 
and real benzodiazepines, as well as the com-
bined use of Lyrica (gabapentin) and opiates.
Also only 5 FPs mentioned having witnessed 
changes in the existing target groups for which 
they provide services. Examples include: OST users 
experiencing more problems in everyday life; the 
MSM chemsex scene is increasing; a decrease in 
NPS use in favour of increased use of pharmaceu-
tical opioids; immigrants returning home from oth-
er EU countries; and immigrants inhaling opioids.
12 FPs started services last year for new groups 
of PWUD. These include: MSM; non-EU immigrants; 
migrants; students from Asia; young people us-
ing non-injectable drugs; PWUD in the chemsex 
scene; immigrants from countries of the former 
USSR;	homeless	populations;	gender	specific	ser-
vices; people returning from other countries; and 
people who buy drugs online.
3 FPs mentioned groups for whom no services are 
yet provided: people who use non-opiate drugs 
(MDMA, amphetamine, LSD, magic mushrooms, 
cocaine), young people, and PWUD at parties.
While C-EHRN monitoring has contributed to a 
better understanding of emerging drug trends, at 
least at the local level, work still needs to be done 
to make full use of these resources. Continuous at-
tention should be paid to the quality of the data. 
New Drug Trends
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Since the beginning of 2020, European countries 
have experienced an unprecedented public 
health threat with the emergence of the coro-
navirus. People who use drugs (PWUD) and harm 
reduction services were affected by the variety 
of virus containment strategies, such as border 
closures, service reductions, and increased po-
lice presence. The C-EHRN Monitoring investi-
gated the effects of the COVID-19 pandemic 
on harm reduction services and on PWUD in FP 
organisations or cities. Data was collected from 
May	to	July	2020,	reflecting	the first wave of the 
pandemic in most FP cities.
For the majority of FPs, the pandemic has af-
fected daily harm reduction practices. Most 
reported a rapid adaptation of services, in-
cluding an increase in programmes and open-
ing hours, new online services, home delivery 
services, and a new need for food and water 
distribution. Some also reported the cessation 
of drop-in services, and disruption in HIV/HCV 
services. Three FPs reported closures during the 
(first	wave	of	the)	pandemic,	and	5	FPs	reported	
that PWUD could not access services in their city 
due to lockdowns. No FPs reported limitations in 
harm reduction supplies from the services that 
remained open. 
While the COVID-19 pandemic has wrought 
many hardships for PWUD and harm reduction 
CSOs, it has also provided a unique opportu-
nity for innovative practices, as well as a few 
potential “silver linings”. Nearly all FPs endorsed 
the pandemic as an opportunity to practice in-
novative harm reduction. Many changes cen-
tred around OST, such as increased length of 
prescriptions and take-home doses; new phone 
or telemedicine services; or increased interest 
in, and enrolment onto, OST. Outreach services 
and access to housing and shelters, and nalox-
one distribution also ranked highly. Other posi-
tive changes include more shelters for people 
experiencing homelessness; new methylpheni-
date prescriptions for stimulant use; more atten-
tion and funding to outreach work and the sup-
ply of sterile syringes; nasal Naloxone training for 
staff and PWUD; distribution of food and hygiene 
products; increased volunteering for outreach; 
and better hygiene and tranquillity in DCRs and 
drop-in sites due to a lower number of service 
users.
FPs reported several difficulties faced by PWUD 
in their countries during the pandemic. Social 
isolation, as well as an increase in mental health 
problems,  was ranked highest by the majority 
of FPs as problematic in their country. Both may 
be related to the severity of the COVID-19 out-
break, as well as the degree of lockdown and 
limitations to services in the region.
From the PWUD perspective, accessibility to 
harm reduction services in their city was par-
tially compromised during the pandemic. OST, 
housing, online harm reduction, and outreach 
COVID-19  
and Harm Reduction
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work were ranked by PWUD as easiest to ac-
cess. The majority of PWUD respondents, how-
ever, noted a reduction in the types of services 
available. About half of PWUD also noted an in-
crease in mental health problems. Other ways 
the COVID-19 pandemic has affected PWUD in 
their city include: problems with the police; dif-
ficulty	gathering	and	meeting	 to	obtain	drugs;	
lack of tourists/lack of money in general; plight 
of the homeless; and lack of drop-in centres for 
social contact. 
Important lessons to be learned from the initial 
response during COVID-19 is that services can be 
adapted rapidly and that expansion of OST, out-
reach services, and home delivery are vital com-
ponents of harm reduction during a pandemic. 
Social isolation and mental health are important 
concerns for PWUD, with increased outreach 
and digital connection/phone services being vi-
tal considerations to overcome these problems. 
Certain pandemic responses demonstrate a 
window of opportunity to overcome political will 
in implementing rapid-scale changes to harm 
reduction services by rolling out new services or 
service changes. Harm reduction services are a 
vital component in a pandemic response in car-
ing for the vulnerable population of PWUD in Eu-
rope. Important considerations for future waves 
of the pandemic are to prioritise expansion of 
outreach services, OST, and housing for vulnera-
ble populations in connection with vital harm re-
duction services. Other infectious disease needs 
(such as HIV/HCV testing and treatment) must 
not be forgotten, and advocacy must continue 
to maintain the needed sterile supplies for harm 
reduction provision during a pandemic. 
“Harm reduction services are a vital component in a pandem-ic response in caring for the vulnerable population of PWUD 
in Europe.
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C-EHRN Monitoring is still in an early developmen-
tal phase; 2020 is only the second year of report-
ing. Given the nature of this monitoring structure, 
and the focus of the work of C-EHRN FP organisa-
tions, most data in this report cannot claim to be 
representative of Europe or the countries in which 
FPs are based. Most FPs work locally, or regional-
ly, and have an in-depth knowledge of how harm 
reduction plays out on the streets. Respecting this 
experience was chosen over national represen-
tativeness to provide a more nuanced analysis of 
the implementation of harm reduction at the local 
level. If, on the one hand, the monitoring loses in its 
ability	to	reflect	a	broader	and	comparative	per-
spective of the different European nations, it gains 
in	reflecting	fundamental	qualitative	data	at	the	
service delivery level that can only be collected 
by CSOs, and which is lacking in several national/
global reports.
Limitations
“Most FPs work locally, or re-gionally, and have an in-depth knowledge of how harm reduction plays out on the 
streets.
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C-EHRN envisions a fair and more inclusive 
Europe, in which people who use drugs, inclu-
ding other related vulnerable and marginali-
zed people, have equal and universal access 
to health and social services without being 
discriminated against and stigmatized.  
We advocate for a harm reduction approach 
that is based on solid evidence and on 
human rights principles, and addresses both 
health and social aspects of drug use.
C CorrelationEuropeanHarm ReductionNetwork
